tirzepatide future
The Prescription Weight Loss Myths That Escalate
By 2030, up to 70% of obese adults could be on tirzepidate therapy, dispelling myths that prescription weight-loss drugs are limited to a niche market. In reality, the rollout of GLP-1 receptor agonists is reshaping clinical practice, payer strategies, and public expectations. Understanding how these changes unfold helps separate hype